<DOC>
	<DOCNO>NCT01639222</DOCNO>
	<brief_summary>The purpose study demonstrate intestinal absorption calcium newly develop calcium carbonate-vitamin D3 chewable tablet formulation increase amount calcium excrete urine decrease parathyroid hormone ( PTH ) serum compare baseline .</brief_summary>
	<brief_title>Human Pharmacology Trial Calcium-vitamin D3 Tablet Healthy Participants</brief_title>
	<detailed_description>The drug test study call Calcichew . This study look calcium absorption healthy postmenopausal woman healthy men . The study enroll approximately 55 healthy adult . All participant receive Calcichew . All participant ask take one chewable tablet time day three day period 2 trial . This trial conduct one clinical site Germany . The overall time participate study 4 week . Participants make 9 visit clinic , contact telephone 7days last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Vitamin D Deficiency</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<criteria>1 . Is healthy postmenopausal woman ( last menses least 2 year sign informed consent follicle stimulate hormone ( FSH ) confirm postmenopausal status ) healthy male age 45 70 year inclusively 2 . Was inform verbally write objective clinical trial , method , anticipate benefit potential risk discomfort she/he might expose , give write consent participation trial prior trialrelated procedure 3 . Is Caucasian 4 . Is assess healthy base physical examination , medical history , clinical laboratory , electrocardiogram ( ECG ) , vital sign 5 . Is nonsmoker ( abstained smoking least 6 month ) 6 . Has body mass index 19 29.4 kg/m^2 ( inclusively ) 1 . Has history clinically significant allergy idiosyncrasy calcium vitamin D3 , inactive ingredient ( ) product 2 . Is lactate pregnant female participant 3 . Female participant : Has positive pregnancy test serum screen urine Day 1 Period 1 4 . Participant previously enrol current clinical trial 5 . Has participate active treatment phase another clinical trial persist pharmacodynamic ( PD ) effect IMP clinical trial exclude ( e.g . patient well treatment free safety followup phase ) ; 10 time pharmacokinetic ( PK ) halflife , whatever longer 30 day minimum prior start clinical trial 6 . Has consider unable unwilling cooperate adequately , i.e . follow clinical trial procedure Investigator instruction adequately ( e.g . language difficulty , etc . ) participant anticipate available scheduled clinical trial visits/procedures 7 . Has dependency situation ( e.g . person keep detention , Investigator current clinical trial , firstdegree relative clinical trial Investigator , employee clinical trial site ) 8 . Has hypersensitivity soya peanut 9 . Abuse alcohol drug 10 . Has consume ethanol within 48 hour prior hospitalization verify alcohol breath test ( AlcotestÂ® ) 11 . Has history current disease might influence trial objective ( e.g. , urinary tract infection , urination problem [ e.g. , prostate hyperplasia ] urinary incontinence , renal insufficiency , nephrolithiasis , sarcoidosis , osteoporosis , calcium deficiency , hyper hypoparathyroidism , hypercalciuria , hypercalcaemia , calcium lithiasis , hyperphosphataemia , hypervitaminosis D , phenylketonuria , diabetes mellitus 12 . Has creatinine clearance accord Modification Diet Renal Disease ( MDRD ) equation &lt; 60 mL/min 13 . Has regular use medication . Treatment biphosphonates past 5 year , amidorone past 6 month , calcium fluoride supplement , diuretic , vitamin D preparation , estrogens estrogen receptor modulators , enzyme induce agent , teriparatide parathyroid hormone ( PTH ( 184 ) ) , bile sequestrants within 3 month screen , drug within 2 week screen ( 6 time halflife respective drug ) whatever long 14 . Has use ultraviolet radiation cabin sunbath longer 1 h 1 week Day 1 Period 1 End Trial examination 15 . Has intake milk milk product , broccoli , darkgreen vegetable , vegetable mustard green family , fatty fish , egg , liver , add salt within 7 day prior hospitalisation 16 . Has unusual diet habit practice vegetarian 17 . Has beverages food contain poppy seed ( i.e . poppy seed roll , poppy seed cake , milk shake contain poppy seed ) 72 hour drug screen avoid interference 18 . Has chinine , grapefruit star fruitcontaining beverage food , St. John 's wort ( know Cytochrome P450 ( CYP450 ) inhibitor inducer ) within 7 day prior hospitalization 19 . Has excessive consumption caffeinated beverage ( five cup coffee equivalent per day ) 20 . Has consumption xanthinecontaining beverage food ( e.g . coffee , black green tea , cola , chocolate ) 48 hour prior hospitalization 21 . Has evidence acute chronic hepatitis B C. Positive test hepatitis B surface antigen ( HBsAg ) , antibody hepatitis B core antigen ( antiHBc ) antibody hepatitis C virus ( antiHCV antibody ) , human immunodeficiency virus ( HIV ) infection screen 22 . Has history gastrointestinal surgery ( except appendectomy ) gastrointestinal condition disease might influence ( calcium ) absorption 23 . Has condition , include laboratory finding finding medical history screening assessment , opinion Investigator , constitute specific risk contraindication participant 's participation trial could interfere trial objective , conduct evaluation 24 . Has comedication require trial .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Drug therapy</keyword>
	<keyword>Increase calcium urinary excretion PTH decrease serum</keyword>
</DOC>